- Novel JEL™ Technology for Periocular Administration
COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) - AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully enrolled and completed dosing the last patient in a Phase 1 trial with wet age-related macular degeneration (wAMD), and/or diabetic macular edema (DME). “We have achieved a major milestone, full enrollment in our Phase 1, Safety Trial in the U.S.” said Diane Tang-Liu, PhD, CEO, President & Co-Founder of AiViva Biopharma. “AIV007 (lenvatinib) is a broad-spectrum tyrosine kinase inhibitor, targeting the convergence of fibrosis, angiogenesis, and inflammation. We believe AIV007, formulated with our proprietary JEL™ technology and administered periocularly, has the potential to address the root causes of wet AMD, DME and many other ocular diseases. We are on target to have the study completed, and full results Q1 2025.”
This Phase 1 trial is a multicenter, open-label, dose-escalation safety clinical trial, with 18 subjects, who have received a single periocular injection of AIV007 and will undergo monthly evaluation for up to 6 months to assess safety, tolerability, biological activity, and the reduction of treatment burden.
About Age-Related Macular Degeneration and Diabetic Macular Edema
AMD is a progressive retinal disease that is the leading cause of blindness in adults over the age of 60, affecting up to 15 million U.S. people. AMD affects the macular, center portion of the retina, that is responsible for central vision and color perception. In patients with wet AMD vision loss is caused by abnormal blood vessels leaking fluid and blood into and beneath the retina. Diabetic macular edema is manifested as retinal thickening and swelling caused by accumulation of intraretinal fluid usually due to blood sugar levels being consistently high. If untreated, chronic macular edema can lead to irreversible damage of the macula and permanent vision loss.
About AiViva Biopharma, Inc.
AiViva is a clinical stage biotech company led by a team of seasoned industry experts with proven track record in drug development and commercialization. AiViva has developed innovative approaches to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. Core competencies include development of novel drugs using proprietary technologies, including JEL™, in specialty therapeutic areas of ophthalmology, dermatology, urology and oncology. Please visit www.aiviva.com to learn more.
Contact:
AiViva Biopharma
office@aiviva.com
-
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related MacularNovel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) - AiViva Biopharma Inc., a clinical-stage2024-08-23
-
BONDW RWA 资产管理:重新定义数字国债交易BONDW RWA 资产管理是由美国国债发行机构(US Treasury Direct Issuance Corporation, USTDIC)发起的数字国债交易平台。USTDIC是全球最大的债券发行机构之2024-08-23
-
中国飞机租赁 (1848.HK) 公布2024年中期业绩 营收稳健增长,持续稳定派息,流动性充裕(香港 - 2024年8月23日)环球航空全产业链解决方案供应商 — 中国飞机租赁集团控股有限公司(「中飞租赁」或本「公司」,连同其附属公司统称「本集团」;港交所股份代号:02024-08-23
-
美鼻“艺术家”贾杰昌与诗致美鼻4.0他是拥有10年整外经验、曾就职于大型三甲医院整形外科的医生;他也是临床医学硕士、《整形美容外科疾病诊疗实践》副主编,他更是用精湛的技术雕琢每一个美丽梦想的“2024-08-23
-
中国重汽公布2024年中期业绩 抢抓市场结构性机遇销量持续增长 盈利能力稳步提升财务摘要 营业收入人民币48,823百万元,同比增长18.0%; 公司权益持有人应占溢利人民币3,294百万元,同比增长39.7%; 整车销售182024-08-23